Press release
NRAS, HRAS, and KRAS Market to Reach USD 14.1 Billion by 2034, Growing at a CAGR of 9.2%
NRAS, HRAS, and KRAS Market
Introduction:
Exactitude Consultancy's latest market research report on the NRAS, HRAS, and KRAS Market forecasts substantial growth from USD 6.5 billion in 2024 to USD 14.1 billion by 2034, growing at a CAGR of 9.2%. This growth is driven by advancements in targeted therapies for cancer, expanding applications in drug discovery, and increasing research investments in molecular oncology.
Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/72672
Key Market Stats & Insights:
• Market Size (2024): USD 6.5 Billion
• Market Size (2034): USD 14.1 Billion
• CAGR (2025-2034): 9.2%
• Key Segments:
o By Product Type: Biologics, Small Molecule Inhibitors
o By Application: Cancer Treatment, Genetic Research, Drug Discovery
o By End-User: Pharmaceutical Companies, Research Institutions, Hospitals
o By Technology: Targeted Therapy, Gene Therapy
o By Distribution Channel: Online Pharmacy, Retail Pharmacy
• Largest Region: North America
Explore Full Report here:
https://exactitudeconsultancy.com/reports/72672/nras-hras-and-kras-market
Market Segmentation:
1. By Product Type: Biologics are leading the market, followed by small molecule inhibitors for targeted therapies in cancer.
2. By Application: Cancer treatment leads the market, with increasing demand for KRAS inhibitors and ongoing research into NRAS and HRAS-related therapies.
3. By Region: North America leads the market, driven by a high number of clinical trials and advanced healthcare infrastructure.
Recent Developments in the Market:
• Increased clinical trials focusing on NRAS, HRAS, and KRAS mutations are driving innovation in molecular targeted therapies.
• Biopharmaceutical companies are focusing on the development of novel small molecule inhibitors targeting these mutations to improve cancer treatment outcomes.
Expert Quote:
"The NRAS, HRAS, and KRAS Market is growing rapidly, driven by advancements in targeted cancer therapies and expanding research in molecular oncology," said Irfan Tamboli, Business Development Executive at Exactitude Consultancy.
Get Your Exclusive Offer with up to 10% Discount
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=72672
Key Drivers and Restraints:
• Drivers: Growing prevalence of cancer, increasing research investments, and advancements in gene therapy technologies.
• Restraints: High cost of treatment and challenges in achieving regulatory approval for novel therapies.
Market Forecast (2024-2034):
The NRAS, HRAS, and KRAS Market is projected to grow at a CAGR of 9.2%, reaching USD 14.1 billion by 2034, driven by innovations in cancer therapies and drug discovery processes.
Conclusion:
The NRAS, HRAS, and KRAS Market is poised for significant growth, presenting new opportunities for pharmaceutical companies, research institutions, and oncology-focused healthcare providers to address unmet needs in cancer treatment.
This report is also available in the following languages : Japanese (NRAS、HRAS、KRAS市場), Korean (NRAS、HRAS、KRAS시장), Chinese (NRAS、HRAS、KRAS시장), French (Marché NRAS, HRAS et KRAS), German (NRAS-, HRAS- und KRAS-Markt), and Italian (Mercato NRAS, HRAS e KRAS), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/72672
Our More Reports:
Plaque Psoriasis in 68 Market
https://exactitudeconsultancy.com/reports/73643/plaque-psoriasis-in-68-market
Parkinson's Disease Market
https://exactitudeconsultancy.com/reports/73645/parkinson-s-disease-market
Parkinson's Disease in 68 Market
https://exactitudeconsultancy.com/reports/73647/parkinson-s-disease-in-68-market
Amyotrophic Lateral Sclerosis Clinical Market
https://exactitudeconsultancy.com/reports/73649/amyotrophic-lateral-sclerosis-clinical-market
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release NRAS, HRAS, and KRAS Market to Reach USD 14.1 Billion by 2034, Growing at a CAGR of 9.2% here
News-ID: 4299072 • Views: …
More Releases from Exactitude Consultancy
Acute Lymphoblastic Leukemia Market to Reach USD 5.9 Billion by 2034, Growing at …
Exactitude Consultancy's new report explores the growth of the Acute Lymphoblastic Leukemia Market, driven by advancements in chemotherapy, targeted therapy, and immunotherapy.
Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/72674
Introduction:
Exactitude Consultancy's latest report on the Acute Lymphoblastic Leukemia Market forecasts robust growth from USD 3.2 billion in 2024 to USD 5.9 billion by 2034, growing at a CAGR of 6.7%. This growth is fueled by innovations in chemotherapy, targeted therapies,…
Chemotherapy-Induced Nausea and Vomiting (CINV) Market Analysis: Growth Drivers, …
Chemotherapy-induced nausea and vomiting (CINV) is one of the most common and distressing side effects of cancer treatment. CINV affects a significant proportion of cancer patients undergoing chemotherapy, impacting their quality of life, treatment adherence, and overall well-being. Nausea and vomiting can range from mild to severe and can occur immediately after chemotherapy or within a few hours to days, making it essential for healthcare providers to effectively manage these…
Thoracic Aortic Aneurysm Market to Reach USD 4.5 Billion by 2034, Growing at a C …
Exactitude Consultancy's new report analyzes the Thoracic Aortic Aneurysm Market, driven by innovations in diagnostic tools, endovascular devices, and surgical procedures.
Introduction:
Exactitude Consultancy's latest report on the Thoracic Aortic Aneurysm Market forecasts steady growth from USD 2.5 billion in 2024 to USD 4.5 billion by 2034, growing at a CAGR of 6.5%. The growth is attributed to advancements in diagnostic technologies, endovascular devices, and minimally invasive surgeries for thoracic aortic aneurysm…
Fill Finish Pharmaceutical Contract Manufacturing Market Emerging Opportunities …
The fill finish pharmaceutical contract manufacturing market refers to the outsourcing of the final steps in the production of pharmaceutical drugs, which includes the filling of drug formulations into their final dosage forms (such as vials, syringes, and cartridges), followed by sealing, labeling, and packaging. This process is critical for ensuring the safety, sterility, and integrity of drug products, particularly in the production of biologics, vaccines, and injectable drugs.
Download Full…
More Releases for NRAS
NRAS/HRAS/KRAS market is projected to reach around USD 12.7 billion by 2034
Among the most infamous oncogenes in cancer biology, the RAS family-particularly NRAS, HRAS, and KRAS-has long been considered "undruggable." Yet in recent years, breakthroughs in targeted inhibitors, allele-specific therapies, and combination strategies are transforming this domain. The NRAS / HRAS / KRAS market is emerging as one of the pivotal battlegrounds in precision oncology, with enormous potential to reshape cancer treatment paradigms across multiple tumor types.
Download Full PDF Sample Copy…
NRAS, HRAS, and KRAS Market Targeting Key Oncogenes in the Era of Precision Medi …
Introduction
The RAS gene family - comprising NRAS, HRAS, and KRAS - plays a pivotal role in regulating cell proliferation, differentiation, and survival. Mutations in these oncogenes are among the most common drivers of cancer, particularly in lung, colorectal, pancreatic, and melanoma cases. Of the three, KRAS mutations are the most prevalent, accounting for a significant percentage of cancers worldwide, while NRAS and HRAS mutations, though less common, are equally critical…
RAS-Targeting Drugs for Precision Oncology Market Detailed Analysis with Accurat …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global RAS-Targeting Drugs for Precision Oncology Market Size, Share & Trends Analysis Report By Drug Type (Small Molecule Inhibitors, Biologics, RNA-Based Therapies, Combination Therapies), Target Mutation (KRAS G12C, KRAS G12D, KRAS G12V, G12R, G12S, G12A, HRAS and NRAS, Pan-RAS), Indication (Non-Small Cell Lung Cancer (NSCLC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC), Other Cancers (e.g., HNSCC,…
RAS-Targeting Drugs for Precision Oncology Market Driven by High Prevalence of R …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global RAS-Targeting Drugs for Precision Oncology Market Size, Share & Trends Analysis Report By Drug Type (Small Molecule Inhibitors, Biologics, RNA-Based Therapies, Combination Therapies), Target Mutation (KRAS G12C, KRAS G12D, KRAS G12V, G12R, G12S, G12A, HRAS and NRAS, Pan-RAS), Indication (Non-Small Cell Lung Cancer (NSCLC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC), Other Cancers (e.g., HNSCC,…
EGFR Kit of AmoyDx, China, Supplier to MoBiTec, Germany, Ranks Top in 2014 Lung …
The European Molecular Genetics Quality Network (EMQN) is an independent organization based in the UK that promotes improvement in the quality of genetic testing by ensuring that diagnostic molecular genetic laboratory test results are accurate, reliable, and comparable.
Amoy Diagnostics, located in Xiamen, China, provides state-of-the-art molecular diagnostic products and services to healthcare providers, academic institutions, and pharmaceutical companies. The company has a rich portfolio of tests that focuses on detecting…
Amoy Diagnostics, China, Expands List of CE-marked Real-Time PCR Kits for Cancer …
Amoy Diagnostics, who recently appointed MoBiTec GmbH as distributor for Germany, proudly announces the availability of further CE-marked detection kits based on a proprietary real-time PCR technology called “ADx-ARMS” for Cancer Diagnostics.
Amoy Diagnostics, headquarted in Xiamen, China, provides state-of-the-art molecular diagnostic products and services to healthcare providers, academic institutions, and pharmaceutical companies. The company has a rich portfolio of tests that focuses on detecting mutations and measuring gene expression in…
